89 related articles for article (PubMed ID: 25055934)
1. Determining the mechanisms of lapatinib-induced diarrhoea using a rat model.
Bowen JM; Mayo BJ; Plews E; Bateman E; Wignall A; Stringer AM; Boyle FM; Keefe DM
Cancer Chemother Pharmacol; 2014 Sep; 74(3):617-27. PubMed ID: 25055934
[TBL] [Abstract][Full Text] [Related]
2. Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.
Raja Sharin RNFS; Khan J; Ibahim MJ; Muhamad M; Bowen J; Wan Mohamad Zain WNI
Biomed Res Int; 2022; 2022():4165808. PubMed ID: 35800225
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
4. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Benter IF; Sarkhou F; Al-Khaldi AT; Chandrasekhar B; Attur S; Dhaunsi GS; Yousif MH; Akhtar S
J Drug Target; 2015; 23(6):506-18. PubMed ID: 26114862
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
6. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea.
Bowen JM; Mayo BJ; Plews E; Bateman E; Stringer AM; Boyle FM; Finnie JW; Keefe DM
Cancer Biol Ther; 2012 Nov; 13(13):1269-75. PubMed ID: 22895076
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Guan Z; Xu B; DeSilvio ML; Shen Z; Arpornwirat W; Tong Z; Lorvidhaya V; Jiang Z; Yang J; Makhson A; Leung WL; Russo MW; Newstat B; Wang L; Chen G; Oliva C; Gomez H
J Clin Oncol; 2013 Jun; 31(16):1947-53. PubMed ID: 23509322
[TBL] [Abstract][Full Text] [Related]
8. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
[TBL] [Abstract][Full Text] [Related]
9. Analysis of dermatologic events in patients with cancer treated with lapatinib.
Lacouture ME; Laabs SM; Koehler M; Sweetman RW; Preston AJ; Di Leo A; Gomez HL; Salazar VM; Byrne JA; Koch KM; Blackwell KL
Breast Cancer Res Treat; 2009 Apr; 114(3):485-93. PubMed ID: 18600445
[TBL] [Abstract][Full Text] [Related]
10. EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells.
Hong S; Gu Y; Gao Z; Guo L; Guo W; Wu X; Shen Y; Sun Y; Wu X; Xu Q
Life Sci; 2014 Dec; 119(1-2):28-33. PubMed ID: 25445223
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
[TBL] [Abstract][Full Text] [Related]
13. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.
Jagiello-Gruszfeld A; Tjulandin S; Dobrovolskaya N; Manikhas A; Pienkowski T; DeSilvio M; Ridderheim M; Abbey R
Oncology; 2010; 79(1-2):129-35. PubMed ID: 21088439
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Fabi A; Merola R; Ferretti G; Di Benedetto A; Antoniani B; Ercolani C; Nisticò C; Papaldo P; Ciccarese M; Sperduti I; Vici P; Marino M; Gori S; Botti C; Malaguti P; Cognetti F; Mottolese M
Expert Opin Pharmacother; 2013 Apr; 14(6):699-706. PubMed ID: 23472669
[TBL] [Abstract][Full Text] [Related]
15. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
17. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
[TBL] [Abstract][Full Text] [Related]
18. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
19. The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats.
Mayo BJ; Secombe KR; Wignall AD; Bateman E; Thorpe D; Pietra C; Keefe DM; Bowen JM
Cancer Chemother Pharmacol; 2020 Apr; 85(4):793-803. PubMed ID: 32060615
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
